Although the mechanism of action of ziconotide has not been established in humans, results in animal models suggest that PRIALT is an N-type calcium channel blocker that is thought to block N-type calcium channels at the dorsal horn of the spinal cord to inhibit pain transmission.6,9,10 PRIALT does not bind to opioid receptors, and its pharmacological effects are not blocked by opioid antagonists.6

Important Safety Information

  • Advise patients of the signs and symptoms of meningitis, such as fever, headache, stiff neck, altered mental status, nausea, vomiting, and occasionally seizures.
  • Reduced levels of consciousness and creatine kinase (CK) elevations have occurred in patients taking PRIALT. Monitor serum CK periodically.
  • For patients being withdrawn from intrathecal opiates, gradually taper over a few weeks and replace with a pharmacologically equivalent dose of oral opiates.
  • The most frequently reported adverse reactions (≥25%) in clinical trials (n=1254 PRIALT-treated patients) were dizziness, nausea, confusional state, and nystagmus. Slower titration of PRIALT may result in fewer serious adverse reactions and discontinuations for adverse reactions.

Please see full Prescribing Information, including BOXED Warning, and click here for additional Important Safety Information.

References: 6. PRIALT [package insert]. Palo Alto, CA: Jazz Pharmaceuticals; February 2013. 9. McGivern JG. Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat. 2007;3(1):69-85. 10. Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe pain. Curr Med Chem. 2004;11(23):3029-3040.
to learn about how
PRIALT may work6,9